Contin M, et al. - In chronically treated patients with multiple sclerosis (MS), researchers performed a single center, open, prospective pilot study to evaluate the potential association between intrasubject 9-tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray plasma profiles and clinical effects prompted by subacute dosing. This study offers the first ever kinetic dynamic findings from THC/CBD oromucosal spray in real MS patients. The preliminary data show that subacute dosing might prompt a subjective clinically significant effect on MS-related spasticity, paralleling cannabinoids measurable plasma concentrations. According to posturographic and motor tests, no significant impact of cannabinoids dosing could be appreciated.